A carregar...

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Clin Risk Manag
Main Authors: Juul, Janelle J, Mullins, Caitlin F, Peppard, William J, Huang, Angela M
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4762434/
https://ncbi.nlm.nih.gov/pubmed/26937194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S71855
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!